(Reuters) - Depomed would book revenue from the sale of the
formulation, ProQuin XR, under the co-exclusive agreement for
the United States, while Watson would receive a portion of the
profits, the companies said in a statement.
Watson and Depomed plan to re-launch ProQuin XR in the
United States by the end of this year.
Read more at Reuters.com Mergers News
formulation, ProQuin XR, under the co-exclusive agreement for
the United States, while Watson would receive a portion of the
profits, the companies said in a statement.
Watson and Depomed plan to re-launch ProQuin XR in the
United States by the end of this year.
Read more at Reuters.com Mergers News
No comments:
Post a Comment